IZL-2003免疫治疗系统治疗肝癌患者40例

Eff icacy of the IZL-2003 immunotherapeutic system in patients with liver cancer: an analysis of 40 cases

目的:探讨IZL-2003免疫治疗系统对肝癌患者的疗效.方法:入选的61例均为肝癌患者,其中治疗组40例,给予毫米波照射联合一般保肝治疗,复合毫米波包括等幅极高频、脉冲极高频、聚能极高频3种,治疗头频率为35-42.8GHz;对照组21例,仅给予一般保肝治疗.治疗前2wk内查血常规、肝功能,1mo内查T细胞亚群、B超或CT等,治疗后2wk内复查血常规,3mo内复查T细胞亚群.结果:肝癌患者白细胞降低组,经免疫治疗系统毫米波照射后可升高白细胞及血色素(P=0.028,0.017),血小板无显著变化.肝癌患者T细胞亚群CD4+细胞(486.45±255.35cells/μL)及CD8+细胞(350.05±246.26cells/μL),均低于正常值,毫米波照射治疗后CD4+及CD8+水平升高;CD4+小于400cells/μL的患者,治疗后CD4+及CD8+均升高(P=0.03,0.067).毫米波照射可有效改善肝癌患者症状,有效率可达80%以上(P<0.05),可有效提高KPS评分,改善生活质量(P<0.01).结论:IZL-2003免疫治疗系统毫米波可增加肝癌患者免疫功能,升高白细胞、血色素,改善生活质量,预防肿瘤复发及转移.

AIM： To evaluate the curative effect of the IZL-2003 immunotherapeutic system in patients with liver cancer. METHODS： Sixty-one patients with liver cancer were divided into treatment group （n = 40） and control group （n = 21）. The patients in the treat- ment group were treated with liver-protecting drugs in combination with 35-42.8-GHz mil- limeter wave. The patients in the control group were treated only with liver-protecting drugs. Routine blood tests and liver function tests were performed within two weeks before treatment. T-cell subgroup detection, B-mode ultrasonic scan or computed tomography （CT） were performed within one month before treatment. Routine blood tests were performed again within two weeks after treatment, and T-cell subgroups were retested within three months after treatment.RESULTS： Millimeter-wave radiation significantly increased white cell count and hemoglobin level in patients with decreased white cell count （P = 0.028 and 0.017, respectively）, but had no significant impact on blood platelet count. The counts of CD4^＋ and CD8^＋T cells in patients with liver cancer were less than normal level （486.45 ± 255.35 and 350.05 ± 246.26 cells/μL, respectively）. Millimeter-wave radiation significantly increased the counts of CD4^＋ and CD8^＋ T cells. In patients with CD4^＋ cell count less than 400 cells/μL, both the counts of CD4^＋ and CD8^＋ cells significantly increased after millimeter-wave radiation （P = 0.03 and 0.067, respectively）. Millimeter-wave radiation could effectively improve the symptoms in patients with liver cancer, and the effective rate was above 80% （P 〈 0.05）. Millimeter-wave radiation could also improve Karnofsky performance scale （KPS） score and life quality in liver cancer patients. CONCLUSION： Millimeter-wave radiation used in the IZL-2003 immunotherapeutic system can enhance immunity, increase white cell count and hemoglobin level, improve life quality, and prevent tumor recurrence and metastasis in patients with liver cancer.